5GH Stock Overview
A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.22 |
| 52 Week High | US$94.50 |
| 52 Week Low | US$27.29 |
| Beta | 0.63 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -45.86% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GH | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | -1.3% |
| 1Y | -45.9% | 15.7% | 7.4% |
Return vs Industry: 5GH underperformed the German Healthcare industry which returned 8.1% over the past year.
Return vs Market: 5GH underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 5GH volatility | |
|---|---|
| 5GH Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5GH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 5GH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,373 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
Guardant Health, Inc. Fundamentals Summary
| 5GH fundamental statistics | |
|---|---|
| Market cap | €5.05b |
| Earnings (TTM) | -€582.92m |
| Revenue (TTM) | €414.64m |
12.2x
P/S Ratio-8.7x
P/E RatioIs 5GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GH income statement (TTM) | |
|---|---|
| Revenue | US$430.76m |
| Cost of Revenue | US$142.63m |
| Gross Profit | US$288.13m |
| Other Expenses | US$893.69m |
| Earnings | -US$605.56m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.91 |
| Gross Margin | 66.89% |
| Net Profit Margin | -140.58% |
| Debt/Equity Ratio | 681.7% |
How did 5GH perform over the long term?
See historical performance and comparison